Key result
VA-ECMO achieves ~78% survival in drug-induced shock, with lower rates when started during CPR.
Why the study?
Acute cardiovascular failure is a leading cause of death in severe poisonings, and VA-ECMO is increasingly used as rescue therapy for cases refractory to optimal conventional treatment, prompting an evaluation of outcomes in drug intoxications.
Does veno-arterial extracorporeal membrane oxygenation (VA-ECMO) improve survival to hospital discharge in patients with drug intoxication-induced refractory cardiogenic shock or cardiac arrest?
Cohort (n=32)
No
Does veno-arterial extracorporeal membrane oxygenation (VA-ECMO) improve survival to hospital discharge in patients with drug intoxication-induced refractory cardiogenic shock or cardiac arrest?
VA-ECMO is a feasible rescue therapy for severe drug intoxications complicated by refractory cardiogenic shock or cardiac arrest, yielding a 78.1% survival to hospital discharge with good neurological outcomes.
Answers are grounded in this paper and cite their sources.
VA-ECMO may support survival in refractory poisoning shock; leaves open whether it improves outcomes versus conventional care.
BACKGROUND AND AIM OF THE STUDY: Acute cardiovascular failure remains a leading cause of death in severe poisonings. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used as a rescue therapeutic option for those cases refractory to optimal conventional treatment. We sought to evaluate the outcomes after VA-ECMO used for drug intoxications in a single-center experience. METHODS: We performed an observational analysis of our prospective institutional database. The primary endpoint was survival to hospital discharge. RESULTS: Between January 2007 and December 2020, 32 patients (mean age: 45.4 ± 15.8 years; 62.5% female) received VA-ECMO for drug intoxication-induced refractory cardiogenic shock (n = 25) or cardiac arrest (n = 7). Seven (21.8%) patients developed lower limb ischemia during VA-ECMO support. Twenty-six (81.2%) patients were successfully weaned after a mean VA-ECMO support of 2.9 ± 1.3 days. One (3.1%) patient died after VA-ECMO weaning for multiorgan failure and survival to hospital discharge was 78.1% (n = 25). In-hospital survivors were discharged from hospital with a good neurological status. Survival to hospital discharge was not statistically different according to sex (male = 75.0% vs. female = 80.0%; p = .535), type of intoxication (single drug = 81.8% vs. multiple drugs = 76.1%; p = .544) and location of VA-ECMO implantation (within our center = 75% vs. peripheral hospital using our Mobile Unit of Mechanical Circulatory Support = 100%; p = .352). Survival to hospital discharge was significantly lower in patients receiving VA-ECMO during on-going cardiopulmonary resuscitation (42.8% vs. 88.0%; p = .026). CONCLUSIONS: VA-ECMO appears to be a feasible therapeutic option with a satisfactory survival rate and acceptable complications rate in poisonings complicated by refractory cardiogenic shock or cardiac arrest.
No takes yet. Share an insight, caveat, or question.
Pozzi et al. (2022) conducted a cohort in Drug intoxication-induced refractory cardiogenic shock or cardiac arrest (n=32). Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was evaluated on Survival to hospital discharge. VA-ECMO for drug intoxication-induced refractory cardiogenic shock or cardiac arrest resulted in 78.1% survival to hospital discharge, with lower survival when initiated during CPR.
Synapse has enriched 10 related papers. Consider them for comparative context: